Pun Pamela Boon Li, Murphy Michael P
MRC Mitochondrial Biology Unit, Wellcome Trust/MRC Building, Cambridge CB2 0XY, UK.
Int J Cell Biol. 2012;2012:843505. doi: 10.1155/2012/843505. Epub 2012 Jun 21.
Glycation, the nonenzymatic glycosylation of biomolecules, is commonly observed in diabetes and ageing. Reactive dicarbonyl species such as methylglyoxal and glyoxal are thought to be major physiological precursors of glycation. Because these dicarbonyls tend to be formed intracellularly, the levels of advanced glycation end products on cellular proteins are higher than on extracellular ones. The formation of glycation adducts within cells can have severe functional consequences such as inhibition of protein activity and promotion of DNA mutations. Although several lines of evidence suggest that there are specific mitochondrial targets of glycation, and mitochondrial dysfunction itself has been implicated in disease and ageing, it is unclear if glycation of biomolecules specifically within mitochondria induces dysfunction and contributes to disease pathology. We discuss here the possibility that mitochondrial glycation contributes to disease, focussing on diabetes, ageing, cancer, and neurodegeneration, and highlight the current limitations in our understanding of the pathological significance of mitochondrial glycation.
糖基化,即生物分子的非酶糖基化,在糖尿病和衰老过程中普遍存在。诸如甲基乙二醛和乙二醛等活性二羰基化合物被认为是糖基化的主要生理前体。由于这些二羰基化合物倾向于在细胞内形成,因此细胞内蛋白质上的晚期糖基化终产物水平高于细胞外蛋白质。细胞内糖基化加合物的形成可能会产生严重的功能后果,如抑制蛋白质活性和促进DNA突变。尽管有几条证据表明存在糖基化的特定线粒体靶点,并且线粒体功能障碍本身与疾病和衰老有关,但尚不清楚线粒体内部生物分子的糖基化是否会特异性地诱导线粒体功能障碍并导致疾病病理。我们在此讨论线粒体糖基化导致疾病的可能性,重点关注糖尿病、衰老、癌症和神经退行性变,并强调目前我们对线粒体糖基化病理意义理解上的局限性。